Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06580301Phase 1Recruiting

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Role: lead

NCT07234474Phase 1Not Yet Recruiting

A Phase I Study of YK012 in Primary Membranous Nephropathy

Role: lead

NCT07010835Phase 1Recruiting

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

Role: lead

NCT06565689Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Role: lead

NCT06574568Phase 1Recruiting

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Role: lead

NCT06982729Phase 1Recruiting

Study of YK012 in Primary Membranous Nephropathy

Role: lead

All 6 trials loaded